Singapore's Cordlife 9-month revenue falls amid suspension of new cord blood collections
Overview
Singapore cord blood bank's 9M revenue fell 14.3% on absence of new collections
Net loss for 9M narrowed by 18.2% to S$5.8 mln due to cost controls
Gross profit margin improved to 58.1% from 57.8% last year
Outlook
Cordlife says priority is meeting regulatory requirements in Singapore
Company expects long-term demand for cord blood banking to remain supported by preventive healthcare trends
Result Drivers
SUSPENSION OF NEW COLLECTIONS - Revenue fell due to continued absence of new cord blood collections in Singapore
COST DISCIPLINE - Net loss narrowed as a result of lower operating expenses and ongoing cost optimisation efforts
EXPENSE REDUCTIONS - Selling, marketing and administrative expenses fell following the suspension of new collections
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
9M Revenue | S$25.2 mln | ||
9M Net Loss | S$5.8 mln | ||
9M Gross Margin | 58.1% | ||
9M Gross Profit | S$14.6 mln |
Reuters Recommended Reads
Nov 10 - New Zealand's Radius Residential Care HY profit jumps on higher occupancy
Nov 10 - New Zealand's Promisia Healthcare HY profit swings positive; raises 2027 outlook
Nov 11 - Singapore Airlines half-year revenue rises, but profit weighed down by fuel costs
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)